17 results
6-K
EX-99.2
HCM
HUTCHMED (China) Limited
8 Aug 22
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
6:24am
with a potentially less toxic, more effective treatment option. We look forward to better understanding the potential of the TAGRISSO® plus savolitinib
6-K
EX-1.1
HCM
HUTCHMED (China) Limited
24 Jun 21
Current report (foreign)
7:33am
, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic
6-K
EX-1.2
HCM
HUTCHMED (China) Limited
24 Jun 21
Current report (foreign)
7:33am
, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous
6-K
EX-99.1
4us989p7dyduw39q
21 Jun 21
HUTCHMED (China) Limited Supplemental and Updated Disclosures
6:27am
6-K
1yvzo
21 Jun 21
HUTCHMED (China) Limited Supplemental and Updated Disclosures
6:27am
6-K
EX-1.1
8f9dblk4s ur0l2
23 Jan 20
Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs
6:40am
6-K
EX-1.1
pboozk0mimx9y 9cpys
30 Sep 19
Current report (foreign)
4:16pm
6-K
EX-1.1
02gt1k 7f
2 Jul 19
Current report (foreign)
4:15pm
6-K
EX-99.1
kadm2s1wsl2vrm4ly6
15 Apr 19
Current report (foreign)
7:21am
20-F
ahbhz9bqdb lp4pbomm
13 Mar 17
Annual report (foreign)
12:00am
F-1
9alij 3cvn0zrc
16 Oct 15
Registration statement (foreign)
12:00am
- Prev
- 1
- Next